RE:RE:RE:RE:mdjbrown....nice find...a bit to add to what you brought...LABS made mention one or two CC's back....at the opening of the CC, Epidiolex sales approx. $900 million annually. Point is, independent if it's the NDA or ANDA, the ANDA calling out LABS FDA DMF, but how about the NDA (new drug application) that requires a new drug monograph from the FDA that we are waiting on....we have a minimum now of TWO drug candidates very close to commercialization.
We could get news of the drug monograph this month for the NDA....new type of anitibiotic?...new cancer drug?, etc, etc, etc,?
We know of 2 now for sure and what did CEO Mr. Pidduck say to shareholders several times during the past several CC's: He said, 'if only one of these are approved it will change the face of the company'.
Once the global pharmaceutical company name is released as the partner with LABS, that press release will HIT a much bigger target audience and draw a much larger crowd of investors into LABS.
It's like in the duck blind, you feel that 'click' on your finger...safety is off, lay low and wait until they come into you, pick your bird and squeeze the trigger. Imho, the safety is off now with LABS.